Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection

被引:46
作者
Foisy, ML [1 ]
Sommadossi, JP [1 ]
机构
[1] Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL 35294 USA
来源
JOURNAL OF CHROMATOGRAPHY B | 1999年 / 721卷 / 02期
关键词
indinavir;
D O I
10.1016/S0378-4347(98)00451-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid, sensitive and specific high-performance liquid chromatography (HPLC) procedure for the quantification of indinavir, a potent human immunodeficiency virus (HN) protease inhibitor, in human plasma is described. Following C-18 solid-phase extraction, indinavir was chromatographed on a reversed-phase C-8 column using a simple binary mobile phase of phosphate buffer-acetonitrile (60:40, v/v). UV detection at 210 nm led to an adequate sensitivity without interference from endogenous matrix components. The limit of quantification was 25 ng/ml with a 0.1 mi plasma sample. The standard curve was linear across the range from 25 to 2500 ng/ml with an average recovery of 91.4%. The mean relative standard deviations for concentrations within the standard curve ranged between 1.4 and 9.7%. Quality control standards gave satisfactory intra- and inter-assay precision (R.S.D. from 3.5 to 15.8%) and accuracy within 15% of the nominal concentration. Sample handling experiments, including HN heat inactivation, demonstrated analyte stability under expected handling processes. The assay is suitable for the analysis of samples from adult and pediatric patients infected with Hn! (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 11 条
[1]  
Balani SK, 1996, DRUG METAB DISPOS, V24, P1389
[2]   Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].
Barry, M ;
Gibbons, S ;
Back, D ;
Mulcahy, F .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209
[3]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF A POTENT AND SELECTIVE HIV PROTEASE INHIBITOR (L-735,524) IN RAT, DOG AND MONKEY PLASMA [J].
CHEN, IW ;
VASTAG, KJ ;
LIN, JH .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 672 (01) :111-117
[4]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[5]   Protease inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus [J].
Lewis, JS ;
Terriff, CM ;
Coulston, DR ;
Garrison, MW .
CLINICAL THERAPEUTICS, 1997, 19 (02) :187-214
[6]  
LIN JH, 1995, DRUG METAB DISPOS, V23, P730
[7]  
*MERCK CO IND, 1997, CRIX PACK INS
[8]  
*US DHHS, 1996, FOOD DRUG ADM
[9]   DETERMINATION OF L-735524, AN HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR, IN HUMAN PLASMA AND URINE VIA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH COLUMN-SWITCHING [J].
WOOLF, E ;
AU, T ;
HADDIX, H ;
MATUSZEWSKI, B .
JOURNAL OF CHROMATOGRAPHY A, 1995, 692 (1-2) :45-52
[10]   Simultaneous determination of unlabeled and deuterium-labeled indinavir in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection [J].
Woolf, EJ ;
Matuszewski, BK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (02) :193-198